Literature DB >> 34275095

The Torino Pericarditis Score: a new-risk stratification tool to predict complicated pericarditis.

Massimo Imazio1, Alessandro Andreis2,3, Marta Lubian2,3, George Lazaros4, Emilia Lazarou4, Antonio Brucato5, Yehuda Adler6,7, Carla Giustetto2, Mauro Rinaldi3, Gaetano Maria De Ferrari2.   

Abstract

Current guidelines on the management of pericardial diseases suggest to identify high-risk features associated with an increased risk of non-idiopathic aetiology and complications. The aim of this study is to evaluate a "pericarditis score" to assess potential complicated pericarditis in order to facilitate initial clinical triage. Consecutive patients with pericarditis were included in a prospective cohort study from January 2017 to December 2018. Complicated pericarditis was defined as pericarditis with a non-idiopathic aetiology, and/or complications, and/or requiring hospitalization. A clinical and echocardiographic follow-up were performed at 1, 3, 6 months and then every 6 months. The study population was randomized in derivation and validation cohorts. In the derivation cohort, female gender (HR 2.57, p = 0.016), fever > 38 °C (HR 2.86, p = 0.005), previous lack of colchicine use (HR 3.16, p = 0.006), previous use of corticosteroids (HR 3.01, p = 0.009), and echocardiographic signs of constriction (HR 2.26, p = 0.018) were selected by a stepwise procedure in a Cox regression model and constituted the score showing a C-statistics of 0.81. In the validation group, the score was significantly associated with the risk of complicated pericarditis (HR 1.438 per 10-points increase, 95% CI 1.208-1.711, p < 0.001) and showed an increase in event rate with increasing score (low risk ≤ 20 points: complicated pericarditis in 4/19 patients, incidence 21%, p = 0.003, high risk > 40 points: complicated pericarditis in 18/24 patients, incidence 75%, p = 0.006). In this study, we developed and tested a simple score to efficiently identify at presentation patients at high risk of developing complicated pericarditis.
© 2021. Società Italiana di Medicina Interna (SIMI).

Entities:  

Keywords:  Pericarditis; Prognosis; Score

Year:  2021        PMID: 34275095     DOI: 10.1007/s11739-021-02803-y

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN: 1828-0447            Impact factor:   3.397


  11 in total

1.  A randomized trial of colchicine for acute pericarditis.

Authors:  Massimo Imazio; Antonio Brucato; Roberto Cemin; Stefania Ferrua; Stefano Maggiolini; Federico Beqaraj; Daniela Demarie; Davide Forno; Silvia Ferro; Silvia Maestroni; Riccardo Belli; Rita Trinchero; David H Spodick; Yehuda Adler
Journal:  N Engl J Med       Date:  2013-08-31       Impact factor: 91.245

Review 2.  Pretreatment with corticosteroids attenuates the efficacy of colchicine in preventing recurrent pericarditis: a multi-centre all-case analysis.

Authors:  Galit Artom; Nira Koren-Morag; David H Spodick; Antonio Brucato; Joseph Guindo; Antoni Bayes-de-Luna; Giovanni Brambilla; Yaron Finkelstein; Brigitte Granel; Antoni Bayes-Genis; Ehud Schwammenthal; Yehuda Adler
Journal:  Eur Heart J       Date:  2005-03-08       Impact factor: 29.983

3.  Corticosteroids for recurrent pericarditis: high versus low doses: a nonrandomized observation.

Authors:  Massimo Imazio; Antonio Brucato; Davide Cumetti; Giovanni Brambilla; Brunella Demichelis; Silvia Ferro; Silvia Maestroni; Enrico Cecchi; Riccardo Belli; Giancarlo Palmieri; Rita Trinchero
Journal:  Circulation       Date:  2008-07-21       Impact factor: 29.690

Review 4.  Colchicine in Pericarditis.

Authors:  Antoni Bayes-Genis; Yehuda Adler; Antoni Bayes de Luna; Massimo Imazio
Journal:  Eur Heart J       Date:  2017-06-07       Impact factor: 29.983

Review 5.  Evaluation and Treatment of Pericarditis: A Systematic Review.

Authors:  Massimo Imazio; Fiorenzo Gaita; Martin LeWinter
Journal:  JAMA       Date:  2015-10-13       Impact factor: 56.272

6.  Prevalence of C-reactive protein elevation and time course of normalization in acute pericarditis: implications for the diagnosis, therapy, and prognosis of pericarditis.

Authors:  Massimo Imazio; Antonio Brucato; Silvia Maestroni; Davide Cumetti; Antonio Dominelli; Giuseppe Natale; Rita Trinchero
Journal:  Circulation       Date:  2011-02-28       Impact factor: 29.690

7.  2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC)Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS).

Authors:  Yehuda Adler; Philippe Charron; Massimo Imazio; Luigi Badano; Gonzalo Barón-Esquivias; Jan Bogaert; Antonio Brucato; Pascal Gueret; Karin Klingel; Christos Lionis; Bernhard Maisch; Bongani Mayosi; Alain Pavie; Arsen D Ristic; Manel Sabaté Tenas; Petar Seferovic; Karl Swedberg; Witold Tomkowski
Journal:  Eur Heart J       Date:  2015-08-29       Impact factor: 29.983

8.  Day-hospital treatment of acute pericarditis: a management program for outpatient therapy.

Authors:  Massimo Imazio; Brunella Demichelis; Iris Parrini; Marco Giuggia; Enrico Cecchi; Gianni Gaschino; Daniela Demarie; Aldo Ghisio; Rita Trinchero
Journal:  J Am Coll Cardiol       Date:  2004-03-17       Impact factor: 24.094

9.  Indicators of poor prognosis of acute pericarditis.

Authors:  Massimo Imazio; Enrico Cecchi; Brunella Demichelis; Salvatore Ierna; Daniela Demarie; Aldo Ghisio; Franco Pomari; Luisella Coda; Riccardo Belli; Rita Trinchero
Journal:  Circulation       Date:  2007-05-14       Impact factor: 29.690

Review 10.  Colchicine efficacy and safety for the treatment of cardiovascular diseases.

Authors:  Alessandro Andreis; Massimo Imazio; Matteo Casula; Stefano Avondo; Gaetano Maria De Ferrari
Journal:  Intern Emerg Med       Date:  2021-03-11       Impact factor: 3.397

View more
  1 in total

Review 1.  Acute Pericarditis: Update.

Authors:  Emilia Lazarou; Panagiotis Tsioufis; Charalambos Vlachopoulos; Costas Tsioufis; George Lazaros
Journal:  Curr Cardiol Rep       Date:  2022-05-20       Impact factor: 3.955

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.